AzTrials
AzTrials

Pancreatic AdenocarcinomaPARANCT06815172

PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos) Study of Risk Factors for Exocrine Pancreatic Neoplasms.

An observational study of Pancreatic Adenocarcinoma, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 1 site in Italy.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The primary objective of the study will be to evaluate the possible association between asbestos exposure (occupational, paraoccupational, environmental and non-occupational) and pancreatic adenocarcinoma. Read more about this study

Who is it for?
Ages 30 to 90 years
Conditions the study is for
Pancreatic Adenocarcinoma
How many people
500 participants
Where
1 siteItaly
Study dates
28 May 2020to Oct 2025
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The maximum duration of the enrollment period will be 32 years, in which 100 participants from Group A and 400 participants from Group B (previously enrolled in the CARA study (Cholangiocarcinoma Aetiology: Role of Asbestos - Study of risk factors of biliary neoplasms) with code 111/2013/UOSS evaluated in the meeting of the Ethics Committee on 19/11/2013 will be recruited. In each case, four hospital checks will be matched, in frequency matching by sex and five-year age group. The choice of this ratio between Group A and Group B (1:4) is justified by the desire to maximize the statistical power of the study.

Who may be able to join

  • Incident cases (new diagnosis) of histologically diagnosed pancreatic adenocarcinoma afferent to the Medical Oncology Unit Prof. Ardizzoni
  • Age 30-90 years
  • Ability to complete the questionnaire
  • Ability to read and understand Italian
  • Signing the informed consent form
  • Patients admitted to the S.Orsola-Malpighi Polyclinic in the ophthalmology, gynecology and urology departments with a diagnosis of cataracts, uterine fibroids and prostate adenoma previously included in the CARA study.
Show all 10Show fewer
  • Age 30-90 years
  • Ability to complete the questionnaire
  • Ability to read and understand Italian
  • Signing the informed consent form

Who cannot join

  • 1. Prevalent cases of the pathology under study
  • Group B
  • Patients with pancreatic adenocarcinoma
  • Patients with a history of malignant neoplastic pathologies
  • Patients suffering from diseases associated with exposure to asbestos: pleuropatias (parietal plaques, diffuse visceral thickening, recurrent effusions and round atelectasis) and pulmonary diseases (alveolitis and asbestosis)
  • Patients in danger of life or hospitalized waiting to undergo surgery for pathologies other than those of inclusion

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Irccs Aoubo

    Bologna, Bologna, 40138

Other trials in Italy

About this study

Official title: PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos): Study of Risk Factors for Exocrine Pancreatic Neoplasms.

The primary objective of the study will be to evaluate the possible association between asbestos exposure (occupational, paraoccupational, environmental and non-occupational) and pancreatic adenocarcinoma. The data collected will be used to generate specific hypotheses on the possible environmental and occupational determinants of the disease.

The study aims to evaluate:

Read more
  1. To evaluate the exposure to asbestos occurred during life, through the use of a standardized questionnaire to be administered to incident cases (newly diagnosed) of histologically diagnosed pancreatic adenocarcinoma afferent to the Medical Oncology Unit Prof. Ardizzoni in Group A, the exposure to asbestos occurred during the course of life;
  2. To produce quantitative estimates of the risk of pancreatic adenocarcinoma associated with asbestos exposure.

2.3. To evaluate the presence of asbestos fibers directly on histological sections of pancreatic cancer of patients exposed to asbestos and undergoing surgery.

Read the detailed description

Pancreatic adenocarcinoma (PDAC) ranks fourth among the causes of cancer death in Western countries, with an incidence almost comparable to mortality. The only therapeutic option with curative intent is surgery, but about 80% of subjects diagnosed with this neoplasm are not candidates for surgery due to the presence of distant metastases (stage IV according to the TNM system) or in the case of locally advanced disease (stage III), with an overall survival at 5 years of less than 10%.

Numerous risk factors have been related to the genesis of PDAC both environmental and genetic.

Environmental factors include cigarette smoking, dietary habits such as high intake of animal proteins and fats, high salt consumption, dehydrated foods, smoked meat, fried foods and smoked sugar, obesity, consumption of high amounts of alcohol, occupational exposure to chlorinated hydrocarbons, chronic pancreatitis and type II diabetes mellitus.

However, most of them are non-specific and there is often no concordance between the different studies conducted to evaluate them.

The role of asbestos exposure as an environmental risk factor in the etiopathogenesis of pancreatic cancer has been poorly investigated to date and with discordant results.

However, as previously demonstrated, asbestos, once inhaled, can enter the lymphatic circulation and therefore the bloodstream by accumulating in the tissues. In particular, a deposit of asbestos fibers in the liver has been demonstrated with the possibility of triggering chronic inflammatory mechanisms underlying the carcinogenic process. Similarly to what has already been demonstrated on the association between occupational exposure to asbestos and the risk of intrahepatic cholangiocarcinoma, this observational study aims to evaluate a possible correlation between this environmental risk factor and pancreatic cancer.

Materials and methods A prospective non-pharmacological single-center observational study will be carried out.

A total of 500 subjects will be involved between Group A and Group B, distributed as follows:

  • 100 subjects of Group A will be patients seen on an outpatient basis and suffering from pancreatic adenocarcinoma with histological confirmation, contacted both during hospitalization and during outpatient or day service access;
  • 400 subjects of Group B will be patients already included as controls in the CARA study (Cholangiocarcinoma Aetiology: Role of Asbestos - code 111/2013/UOSS evaluated in the meeting of the Ethics Committee of 19/11/2013) admitted to the Polyclinic in the ophthalmology, urology and gynecology departments not affected by the pathology under study, nor by pathologies associated with exposure to asbestos.

Upon obtaining informed consent, all subjects in Group A will be administered a standardized questionnaire (once per patient), containing questions from the ReNaM questionnaire (National Mesothelioma Registry), the work history of the subjects and some questions related to known risk factors.

Descriptive population statistics will be presented, stratifying according to case or control status. To estimate the strength of the association between asbestos exposure and pancreatic cancer risk, uni- and multivariate logistic models will be conducted.

On 30 cases subjected to the ReNaM questionnaire, the presence of asbestos fibers directly on histological sections of pancreatic cancer, obtained following surgical resection for curative therapeutic purposes according to the standard of care, will be evaluated.

Samples will be evaluated using light microscopy and scanning electron microscopy with attached chemical microprobe to highlight the presence of fibers within the tumor tissue.

Keywords
asbesto, cancer, risk factor, pancreatic adenocarcinoma
Medical subject headings
Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06815172
Study groupRoleWhat they receive
Group A100 subjects will be patients seen on an outpatient basis and suffering from pancreatic adenocarcinoma with histological confirmation, contacted both during hospitalization and during outpatient access or in day service
Group B400 subjects will be patients already included as controls in the CARA study (Cholangiocarcinoma Aetiology: Role of Asbestos - code 111/2013/UOSS evaluated in the meeting of the Ethics Committee of 19/11/2013) admitted to the Polyclinic in the ophthalmology, urology and gynecology departments not affected by the pathology under study, nor by pathologies associated with exposure to asbestos.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. primary objective

    The primary objective of the study will be to evaluate the possible association between asbestos exposure (occupational, paraoccupational, environmental and non-occupational) and pancreatic adenocarcinoma. The data collected will be used to generate specific hypotheses on the possible environmental and occupational determinants of the disease.

    Measured: From enrollment to the administration of the standardized questionnaire (once per patient), containing questions from the ReNaM (National Mesothelioma Registry) for up to 60 days.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Feb 2025
  2. Study start28 May 2020
  3. Primary completionSep 2025 (estimated)
  4. Study completionOct 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06815172
Sponsor's protocol ID
PARA
Other IDs
RC-2022-2773381
Acronym
PARA
Status last verified
Dec 2024
First submitted
10 Jan 2025
Last updated
7 Feb 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Pancreatic Adenocarcinoma, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 7 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

primary objective (time frame: From enrollment to the administration of the standardized questionnaire (once per patient), containing questions from the ReNaM (National Mesothelioma Registry) for up to 60 days.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in